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Abstract
Background
Intravenous morphine (IVM) is the most common strong analgesic used in trauma, but is
associated with a clear time limitation related to the need to obtain an access route. The
intranasal (IN) route provides easy administration with a fast peak action time due to high
vascularization and the absence of first-pass metabolism. We aimed to determine whether
IN sufentanil (INS) for patients presenting to an emergency department with acute severe
traumatic pain results in a reduction in pain intensity non-inferior to IVM.
Methods and findings
In a prospective, randomized, multicenter non-inferiority trial conducted in the emergency
departments of 6 hospitals across France, patients were randomized 1:1 to INS titration
(0.3 μg/kg and additional doses of 0.15 μg/kg at 10 minutes and 20 minutes if numerical
pain rating scale [NRS] > 3) and intravenous placebo, or to IVM (0.1 mg/kg and additional
doses of 0.05 mg/kg at 10 minutes and 20 minutes if NRS > 3) and IN placebo. Patients, clin-
ical staff, and research staff were blinded to the treatment allocation. The primary endpoint
was the total decrease on NRS at 30 minutes after first administration. The prespecified
non-inferiority margin was −1.3 on the NRS. The primary outcome was analyzed per proto-
col. Adverse events were prospectively recorded during 4 hours. Among the 194 patients
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enrolled in the emergency department cohort between November 4, 2013, and April 10,
2016, 157 were randomized, and the protocol was correctly administered in 136 (69 IVM
group, 67 INS group, per protocol population, 76% men, median age 40 [IQR 29 to 54]
years). The mean difference between NRS at first administration and NRS at 30 minutes
was −4.1 (97.5% CI −4.6 to −3.6) in the IVM group and −5.2 (97.5% CI −5.7 to −4.6) in the
INS group. Non-inferiority was demonstrated (p < 0.001 with 1-sided mean-equivalence t
test), as the lower 97.5% confidence interval of 0.29 (97.5% CI 0.29 to 1.93) was above the
prespecified margin of −1.3. INS was superior to IVM (intention to treat analysis: p = 0.034),
but without a clinically significant difference in mean NRS between groups. Six severe
adverse events were observed in the INS group and 2 in the IVM group (number needed to
harm: 17), including an apparent imbalance for hypoxemia (3 in the INS group versus 1 in
the IVM group) and for bradypnea (2 in the INS group versus 0 in the IVM group). The main
limitation of the study was that the choice of concomitant analgesics, when they were used,
was left to the discretion of the physician in charge, and co-analgesia was more often used
in the IVM group. Moreover, the size of the study did not allow us to conclude with certainty
about the safety of INS in emergency settings.
Conclusions
We confirm the non-inferiority of INS compared to IVM for pain reduction at 30 minutes after
administration in patients with severe traumatic pain presenting to an emergency depart-
ment. The IN route, with no need to obtain a venous route, may allow early and effective
analgesia in emergency settings and in difficult situations. Confirmation of the safety profile
of INS will require further larger studies.
Trial registration
ClinicalTrials.gov NCT02095366.
EudraCT 2013-001665-16.
Author summary
Why was this study done?
• To relieve acute pain in an emergency room, the priorities are analgesia as early as possi-
ble, using an agent with rapid onset of action and powerful enough to achieve a level of
pain as low as possible.
• Intravenous morphine is the most commonly used strong analgesic, but the need to
obtain intravenous access is a clear limitation to its rapid use.
• The intranasal route using sufentanil spray could provide rapid easy administration
with fast peak action time.
Intranasal sufentanil in severe trauma pain
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What did the researchers do and find?
• We compared the effectiveness of intranasal sufentanil to that of intravenous morphine
for patients presenting at an emergency room with acute severe traumatic pain.
• Patients were randomly assigned to receive intranasal sufentanil and intravenous pla-
cebo, or intravenous morphine and intranasal placebo.
• The 2 treatments gave similar levels of relief from pain according to self-assessments of
pain by the patients.
What do these findings mean?
• In the emergency room, intranasal sufentanil is feasible and not inferior to intravenous
morphine in reducing severe pain due to traumatic injury at 30 minutes.
• Adverse events were frequent, as expected for opioids, but rarely serious. Larger studies
are needed to confirm safety.
• The use of intranasal sufentanil might provide an easy and time-saving solution in the
management of acute pain.
Introduction
Pain is the most common symptom presented by patients in hospital emergency departments,
particularly in the context of trauma. It is estimated that fewer than half of patients receive
analgesics within 1 hour of arrival [1–3]. Despite the wide range of therapeutic methods avail-
able, their prompt administration is hindered by the availability of the necessary material con-
ditions. The 3 priorities for emergency acute pain treatment are implementation as early as
possible, rapid onset of action, and powerful enough to reach a level of pain as low as possible.
Intravenous morphine (IVM) is the most common strong analgesic, but is associated with a
clear time limitation related to the need to obtain an access route. Inhaled, intramuscular, and
sublingual pathways have been tested for many years with gaseous molecules or adapted for-
mulations [4–7]. The intranasal (IN) route provides easy administration with a fast peak action
time due to high vascularization and the absence of first-pass metabolism [8–10]. Many mole-
cules have been evaluated, but they need to be at high concentrations (small volume vaporized)
and liposoluble to be effective. Despite studies on fentanyl showing encouraging results and
adequate IN-to-systemic pharmacokinetics [10–12], its use is still scarce in emergency practice.
Sufentanil has the advantage of being a stronger opioid, well known by emergency physicians
and intensivists, and available in high concentration, with known rapid peak action time
(about 5 minutes) via an intravenous (IV) route [13]. However, the short-term analgesic action
of sufentanil administered by a nasal route on acute severe pain is still poorly evaluated [14–
17]. Apart from non-randomized and open-label studies [14,15], 2 recent studies evaluated IN
sufentanil (INS) in good methodological conditions. Lemoel et al. [16] compared INS to
venous analgesia but without a standardized comparator: the venous analgesia did not system-
atically include an opiate. Sin et al. [17] performed a low-powered study (30 patients) and
showed no difference in analgesia, but the study was not designed to prove non-inferiority.
Intranasal sufentanil in severe trauma pain
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Our aim was therefore to assess the non-inferiority of the analgesic effect and safety of titrated
INS compared to titrated IVM administered to patients with non-life-threatening trauma.
Methods
Study design and participants
The ALGOFINE trial was designed as a multicenter, double-blind, randomized, controlled
non-inferiority trial. The full protocol for this trial is available as S1 Text. Adult patients (18 to
75 years old) presenting with traumatic pain self-evaluated as�6/10 on a numerical pain rat-
ing scale (NRS) were recruited at triage in 6 hospital emergency departments (Grenoble Alpes
University Hospital [Grenoble], Metropole-Savoie Hospital [Chambery], Centre Hospitalier
Annecy Genevois [Annecy], Albertville–Moutiers Hospital [Albertville], Saint-Jean-de-Mauri-
enne Hospital [Saint-Jean-de-Maurienne], and Voiron Hospital [Voiron]). Patients were not
enrolled if they presented with 1 of the following criteria at triage: pain of non-traumatic ori-
gin; chronic respiratory, renal, or hepatic insufficiency; any history of drug addiction; past
medical or surgical sinus pathology; oxygen saturation < 90%; systolic blood pressure < 90
mm Hg; traumatic brain injury with a Glasgow Coma Scale score< 14; opioid allergy; facial
trauma; patient unable to understand or self-assess using a NRS; opiate administration within
6 hours before admission; or weight > 100 kg. Information regarding procedures, possible
adverse events or inefficacy, and data privacy was given to the participants before obtaining
signed consent. In particular, participation in the study was proposed during the first few min-
utes of triage, given the urgency of their need for pain relief. They were informed that in view
of their level of pain, IVM was normally indicated, and would be offered by the doctor in
charge. An explanation regarding sufentanil, IN administration, and the principles of random-
ization and blinding were given while the nurse in charge obtained the venous route required
even if the patient declined to participate.
A group of patients recruited in a pre-hospital setting by a mobile emergency unit was
planned. They are not included in the present study population, and the results of this prespec-
ified ancillary study are not described here (at the reviewers’ request).
The study was investigator initiated and conducted in accordance with the principles of the
Declaration of Helsinki. The protocol (EudraCT 2013-001665-16; ClinicalTrials.gov
NCT02095366) was approved by the regional ethics board on May 15, 2013 (Rhone-Alpes
Auvergne Clinical Research Centers ethics committee CECIC IRB N˚ 2013-001665-16), the
national commission for liberties and data protection (Commission Nationale de l’Informa-
tique et des Liberte´s), and the national drug safety agency (Agence Nationale de Se´curite´ du
Me´dicament et des Produits de Sante´). All information regarding procedures, risks, and data
privacy was made known to the participants before obtaining signed consent. This study is
reported as per the Consolidated Standards of Reporting Trials (CONSORT) guideline (see S1
CONSORT Checklist).
Randomization and masking
All clinical and research staff as well as patients were blinded to the treatment allocation except
for the nurse in charge of the preparation of the treatments. Treatments were prepared from
randomized packs in a dedicated room, and syringes labeled only “IV” and “IN” were given to
the investigator. All study drugs were packaged in blinded trial packs by a clinical trial pharma-
cist who was blinded to interventions and outcomes. Randomization (1:1) in parallel groups
was pre-performed in blocks of random sizes and stratified by center using dedicated software
hosted in Grenoble Alpes University Hospital. The randomization list was handed over to the
central pharmacy in charge of preparing the packs.
Intranasal sufentanil in severe trauma pain
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Procedures
At inclusion, and at 10 minutes and 20 minutes after inclusion if NRS remained>3, each
patient received both a single dose of active agent and a single dose of placebo via the IV and
IN routes. In the INS group, an initial dose of 0.30 μg/kg sufentanil (0.15 μg/kg in each nostril)
was administered. Additional doses (0.15 μg/kg) were administered at 10 and 20 minutes in 1
of the nostrils if NRS remained >3/10. A stock solution at 50 μg/ml of sufentanil was sampled
at each administration according to the patient’s weight with a conventional 1-ml syringe and
atomized with a nasal mucosal atomization device (MAD, Wolfe Tory Medical, Salt Lake City,
UT, US). The MAD is a simple device with a Luer lock tip that is readily connected to the
syringe and provides complete vaporization of the contents. The MAD allows blinded proce-
dures and precise dosage according to the patient’s weight since a standard syringe is used
rather than a commercial ready-to-use system.
In the IVM group, an initial dose of 0.1 mg/kg was administered, and additional doses of
0.05 mg/kg at 10 and 20 minutes if the NRS remained >3/10. In both groups, placebo was
0.9% sodium chloride, administered either intravenously or by nasal atomization in the same
volume that would have been given for the active treatment. During the first 30 minutes, the
physician in charge was authorized to use co-analgesics, except for sedatives and strong opi-
ates. After an outcome evaluation at 30 minutes, the physician in charge was informed of the
nature and amount of drug administered in order to increase medication if necessary.
Data collection and outcome measures
The primary endpoint was analgesia efficacy defined as a decrease in pain on the NRS between
the first administration and 30 minutes later. Secondary endpoints included analgesia efficacy
at 10 and 20 minutes defined by a decrease in NRS, and the incidence of any serious and non-
serious adverse events up to 4 hours after the first administration. Vital parameters were col-
lected every 10 minutes over 1 hour, including Ramsay Sedation Scale and Glasgow Coma
Scale scores. Side effects and symptoms were recorded throughout the procedure, including
those collected by posing specific questions to the patient every 10 minutes. The patient’s satis-
faction regarding the procedure was assessed at 30 minutes.
Study data were collected and managed using the REDCap (Research Electronic Data Cap-
ture) electronic data capture tool hosted at Grenoble Alpes University Hospital [18]. REDCap
(Research Electronic Data Capture) is a web-based application to support data capture, provid-
ing validated data entry, audit trails for tracking data processing and export, automated export
procedures to download data to commonly used statistical packages, and procedures for
importing data [18].
Statistical analysis
Sample size, power, and statistical methods. As a non-inferiority study, the threshold
was based on a clinically meaningful difference in efficacy (NRST30 − NRST0) between the 2
treatments of −1.3 [19,20]. From previous studies it was estimated that the standard deviation
of the reduction in pain would be 2.8 [21]. With a sample size of 198 patients (99 in each
group), a 2-group design would provide at least 80% power to reject the null hypothesis (corre-
sponding to a loss of efficacy greater than or equal to 1.3 [19]), in favor of the alternative
hypothesis, corresponding to a gain in efficacy or a loss of efficacy of less than 1.3, assuming
that the expected mean difference was 0, the common standard deviation 2.8 [21], and the
level of significance 2.5%. The target sample size was therefore set at 218 participants (109 in
each arm) to account for potential protocol deviations or premature interruptions. The sample
Intranasal sufentanil in severe trauma pain
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size calculation was performed using NQuery Advisor 7.0 software (Statistical Solutions, Bos-
ton MA, US).
Data analysis. Non-inferiority was determined on the basis of a 1-sided mean-equiva-
lence t test (two 1-sided t tests approach, TOSTT procedure) [22] on the per protocol popula-
tion (primary endpoint: NRS efficacy [NRST30 − NRST0]) and confirmed, for sensitivity
reasons, on the modified intention to treat population, according to recommendations. Imple-
mentation of the modified intention to treat analysis required the replacement of missing data;
this was performed using the multiple imputation method. Ten imputations of the missing
data were used in the multiple imputation process. Following the reviewers’ recommendations,
we performed a linear regression adjusted for baseline pain score and site.
We evaluated the superiority of the INS treatment over IVM at 30 minutes in the modified
intention to treat population using a 2-sample Student t test. The superiority analysis was
planned after the beginning of patient enrollment (and before any unblinding), if non-inferi-
ority was met. We also compared the efficacy of the INS treatment to IVM treatment at the dif-
ferent time points (NRST10 − NRST0 and NRST20 − NRST0) in the intention to treat population
using a 2-sample Student t test. We evaluated the efficacy of INS treatment and IVM at differ-
ent times within each group (NRST0 versus NRST10 and NRST0 versus NRST20) in the per pro-
tocol population and in the modified intention to treat population using a paired Student t test
(or a Wilcoxon test if necessary). We compared the incidence of serious and non-serious
adverse events between the groups using a chi-squared test, or a Fisher exact test if necessary
(expected frequency less than 5). We summarized patient satisfaction (100-point scale) as
median and interquartile range (IQR), compared using a Mann–Whitney test (the test used
was not prospectively planned in the analysis plan). Statistical analyses were performed using
Stata 13.1 software (StataCorp, College Station, TX, US).
Results
Patient characteristics
Between November 4, 2013 and April 10, 2015 we assessed a total of 194 patients presenting
with acute traumatic pain for eligibility; 157 were included in the emergency department
cohort and randomized, and 155 initiated the treatment. Nineteen patients were excluded
from the per protocol analyses, mainly for underdosing (n = 7) or overdosing (n = 8) (see Fig 1
for detailed patient flow chart), yielding n = 69 for the IVM group and n = 67 for the INS
group. Although recruitment was slower than expected over the planned duration of the study,
the power remained above 80%, with an effective standard deviation in reduction in pain of
2.1 in post hoc analysis. The 2 treatment groups were well balanced with respect to baseline
characteristics, with the exceptions of the male/female ratio and the number of patients who
received other concomitant analgesia (IVM 33% versus INS 22%; Table 1). The mean NRS at
baseline (T0) was 7.6 (95% CI 7.3–7.9) in the IVM group and 7.9 (95% CI 7.6–8.2) in the INS
group. The median total dose of IVM administered was 12.5 mg (IQR 10.0 to 15.1), and the
median total dose of INS was 36.0 μg (IQR 30.0 to 42.7). Ten minutes after the first administra-
tion, 59 (85.5%) patients in the IVM group received a second dose and 60 (89.6%) patients in
the INS group received a second dose. Twenty minutes after the first administration, 42
(60.9%) patients in the IVM group received a third dose and 38 (56.7%) patients in the INS
group received a third dose.
Primary endpoint (non-inferiority)
The mean difference between NRS at first administration and NRS at 30 minutes was −4.1
(97.5% CI −4.6 to −3.6) in the IVM group and −5.2 (97.5% CI −5.7 to −4.6) in the INS group
Intranasal sufentanil in severe trauma pain
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(per protocol analysis). Non-inferiority was met (p< 0.001), as the lower 97.5% confidence
interval of 0.29 was greater than the prespecified non-inferiority margin of −1.3 (mean differ-
ence in NRS variation between groups 1.11, 97.5% CI 0.29 to 1.93).
Fig 1. Enrollment, randomization, and follow-up of study participants. INS, intranasal sufentanil; IVM, intravenous morphine.
https://doi.org/10.1371/journal.pmed.1002849.g001
Intranasal sufentanil in severe trauma pain
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In the intention to treat analysis, the mean NRS difference between first administration and
at 30 minutes was −4.4 (97.5% CI −4.9 to −3.8) in the IVM group and −5.1 (97.5% CI −5.7 to
−4.5) in the INS group. Non-inferiority was met (p< 0.001), as the lower 97.5% confidence
interval of −0.05 was greater than the prespecified non-inferiority margin of −1.3 (mean differ-
ence of NRS variation between groups 0.74, 97.5% CI −0.05 to 1.54).
After adjusting for center (hospital) and the baseline level of pain, the difference in NRS
reduction between groups was 0.87 (97.5% CI 0.19 to 1.54, p = 0.012).
Table 1. Baseline characteristics of participants (per protocol).
Characteristic IVM (n = 69) INS (n = 67)
Patient characteristic
Median [IQR] age (years) 41 [28 to 54] 38 [30 to 55]
Men 40 (58) 31 (46)
Median [IQR] weight (kg) 74 [61 to 83] 70 [60 to 80]
Trauma area�
Head 2 (2.9) 1 (1.5)
Shoulder 7 (10.1) 12 (17.9)
Arm/elbow 12 (17.4) 9 (13.4)
Wrist or hand 17 (24.6) 8 (11.9)
Thorax wall 3 (4.4) 5 (7.5)
Rachis 12 (17.4) 8 (11.9)
Pelvis/hip 10 (14.5) 5 (7.5)
Leg/knee 8 (11.6) 13 (19.4)
Ankle or foot 11 (15.9) 13 (19.4)
Vital parameters at inclusion
Median [IQR] HR (per minute) 76 [68 to 91] 74 [67 to 84]
Median [IQR] RR (per minute) 16 [15 to 19] 18 [15 to 20]
Median [IQR] SpO2 (%) 99 [97 to 100] 99 [97 to 100]
Median [IQR] MAP (mm Hg) 98 [91 to 104] 94 [85 to 103]
Median [IQR] NRS (/10) 8 [7 to 8] 8 [7 to 9]
Co-analgesia� 23 (33) 15 (22)
Paracetamol 22 (32) 15 (22)
Codeine 2 (3) 2 (3)
Ketoprofen 4 (6) 1 (1)
Inclusion site
Grenoble (north site) 41 (59.4) 42 (62.7)
Grenoble (south site) 2 (2.9) 2 (3.0)
Saint-Jean-de-Maurienne 10 (14.5) 8 (11.9)
Annecy 9 (13.0) 8 (11.9)
Chambery 4 (5.8) 3 (4.5)
Albertville 3 (4.3) 3 (4.5)
Voiron 0 (0) 1 (1.5)
Values are numbers (percentages) unless stated otherwise.
�A patient could have multiple traumatized areas or concomitant analgesics.
HR, heart rate; INS, intranasal sufentanil; IQR, interquartile range; IVM, intravenous morphine; MAP, mean arterial
pressure; NRS, numerical pain rating scale; RR, respiratory rate.
https://doi.org/10.1371/journal.pmed.1002849.t001
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Secondary endpoints
Superiority. In superiority analysis, INS was superior to IVM for NRS pain reduction at
30 minutes in the intention to treat population (p = 0.034 for superiority), with a clinically
nonsignificant difference in mean NRS between groups of 0.7. A significant decrease in NRS
was observed after 10 minutes within both groups (mean difference −2.7, 95% CI −3.1 to −2.2,
p< 0.001, for the IVM group and −2.1, 95% CI −2.5 to −1.7, p< 0.001, for the INS group,
intention to treat), as well as after 20 minutes (mean difference −3.8, 95% CI −4.2 to −3.3, p<
0.001, for the IVM group and −4.0, 95% CI −4.5 to −3.5, p< 0.001, for the INS group, inten-
tion to treat). In a between-group comparison, no differences were found in NRS reduction at
10 and 20 minutes. Variations in NRS with time in each group are presented in Fig 2. In a sub-
group analysis, self-assessed pain (NRS) was 3 or lower at 30 minutes for 34 (49.3%) patients
in the IVM group and for 48 (71.6%) in the INS group (absolute difference = 22.3%, relative
difference = 45.2%, p = 0.01; Fig 3). Sixteen patients in each group (23.2% in the IVM group
and 23.9% in the INS group) received rescue pain medication by the physician in charge after
unblinding.
Adverse events and patient satisfaction. There were no statistically significant differ-
ences between groups in recorded mild or serious adverse events in either the per protocol
(Table 2) or the intention to treat populations. The most frequent adverse events observed
were dizziness, hot flushes, and nausea or vomiting (Table 2). Hypoxemia (SpO2 < 90%)
occurred in 3 (4.5%) patients in the INS group and in 1 (1.5%) patient in the IVM group. Bra-
dypnea (respiration rate< 10/minute) was observed in 2 (3%) patients, both in the INS group.
Finally, hypotension was reported in 1 (1.5%) patient in each group. None of the patients
required naloxone, ventilation support, or vasopressors. Two patients required oxygen admin-
istration (3 l/min) during 10 minutes. The number of patients needed to harm was 17 (95% CI
7–56) for serious adverse events, including 33 (95% CI 12–38) for hypoxemia and 34 (95% CI
13–53) for bradypnea.
The median patient satisfaction assessed on a 100-point scale at the end of the procedure
was 80 (IQR 60 to 92.5) in the IVM group and 80 (IQR 70 to 100) in the INS group (p = 0.34).
Discussion
In this randomized, double-blind trial comparing IV and IN opioid analgesia in emergency
departments, INS was feasible and non-inferior to IVM in reducing severe pain from trau-
matic injury, at 30 minutes. Furthermore, the results suggest that the INS regimen (0.30 μg/kg
and then 0.15 μg/kg every 10 minutes) is superior to IVM (0.1 mg/kg and then 0.05 mg/kg
every 10 minutes) at 30 minutes, with a median decrease in NRS> 5, without, however, reach-
ing a between-group difference in NRS reduction large enough to be considered clinically sig-
nificant (i.e., a difference in NRS� 1.3) [19,20]. The analgesic effectiveness of INS was
observed after the first 10 minutes, with a mean within-group reduction in NRS of 2.1. Adverse
events were frequent, as expected for opioids, but rarely serious, with no significant difference
between the 2 groups, despite an imbalance observed to the detriment of INS.
So far, the use of INS has been mainly studied in palliative or pediatric patients, mostly in a
perioperative context and in combination with other methods of sedation [23–29]. Only a few
studies [14–17] have tested INS for acute pain management in the context of emergency prac-
tice. Two studies were conducted as non-randomized open-label trials [14–15], making the
interpretation of efficacy and side effects difficult. In these 2 studies, 15 and 40 patients suffer-
ing from distal extremity injury received a single dose of 0.5 μg/kg of INS. The average pain
score at 30 minutes was lowered by 4.3 points [14] and 4.7 [15], respectively. Some adverse
effects were reported, such as dysphoria (46.6%), nausea (13.3%), and dizziness (7.5%), but no
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apnea was observed. More recently 2 monocentric randomized controlled trials versus placebo
have been published [16–17]. Lemoel et al. [16] administered a single dose of 0.4 μg/kg of INS
(or placebo) to 144 patients admitted to the emergency department for a recent (<6 h) isolated
limb injury. Usual IV pain treatment was given to every patient, with multimodal analgesics
including IV opioids if needed. The percentage of patients with satisfactory pain relief
(NRS� 3) was better in the sufentanil group (72.2%) than in the control group (51.4%). How-
ever, a higher rate of side effects was observed in the sufentanil group (12.5% more bradypnea
and 24% more nausea) than in controls. This is probably due to the cumulative administration
of opioids in the active group, who could receive both INS and IVM. Sin et al. [17] compared
the administration of a single dose of 0.7 μg/kg of INS versus 0.1 mg/kg of IVM in 60 adult
patients who presented to the emergency department with acute pain. They did not find any
difference in NRS between the 2 groups 10 minutes after drug administration. Despite the
high dose of sufentanil they used, they reported that only 7.5% of cases had dizziness, and
none had dysphoria or apnea. All of these published studies considered the effects of a single
administration of INS. Our protocol aimed to respect the principle of opioid titration, with
repeated administrations of divided doses. Our patients received an average total dose of 36 μg
of sufentanil in comparison with the average dose of 37.7 μg administered by Sin et al. [17].
Surprisingly, despite our titration strategy, we reported more frequent side effects than Sin
et al. This might be due to the small number of patients they studied and also to the attention
we paid to ensuring we collected every side effect in our non-inferiority design protocol.
Fig 2. NRS at the different time points by group. The box extends from the 25th to the 75th percentile, and the whiskers are drawn down to the 5th
percentile and up to the 95th. Points below and above the whiskers are drawn as individual points. No significant differences were observed in NRS values
between groups at the 10-minute and 20-minute time points. IN sufentanil was non-inferior and superior to IV morphine in NRS reduction from drug
administration to 30 minutes (NRST30 − NRST0). IN, intranasal; IV, intravenous; NRS, numerical pain rating scale.
https://doi.org/10.1371/journal.pmed.1002849.g002
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Indeed, no studies to our knowledge to date have been methodologically designed to study
the non-inferiority of INS versus IVM in terms of analgesic efficacy and side effects for trauma
in adults, which is the most frequent situation encountered by emergency physicians. We
designed our study to assess a strong, fast-acting opioid, hoping to observe a rapid and clear
action that we could compare with morphine from the first 5 minutes onwards. In a titration
protocol comparable to that commonly used for IVM, both non-inferiority and superiority
were observed for INS at 30 minutes. The first 30 minutes is the time usually needed to obtain
an IV cannula; this duration is shorter than the time of action of most other analgesics, other
than inhaled therapies such as nitrous oxide or methoxyflurane [4,30]. Moreover, the effect of
INS appears convincing as early as 5 minutes after administration, with a reduction in pain
comparable to that obtained with IVM. The duration of action of sufentanil is short and
depends on the route of administration used. Intravenously it has a half-life of about 15 min-
utes; this half-life is longer by a sublingual route due to further absorption [31,32]. When
administered intranasally, the effect is probably intermediate [10,11], but remains short and
results in an expected analgesia of about 45 minutes’ duration. Therefore, INS could be useful
for the initiation of analgesia aimed at easing the pain as quickly as possible. In the context of
Fig 3. Patients with NRS� 3 at the different time points by group. �Declared NRS was 3 or less at 30 minutes for 49.3% of patients in the IV morphine group
and 71.6% in the IN sufentanil group (p = 0.01). IN, intranasal; IV, intravenous; NRS, numerical pain rating scale.
https://doi.org/10.1371/journal.pmed.1002849.g003
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the growing “opioid epidemic,” this mode of use could have the advantage of reducing the pre-
scription of subsequent oral opioids responsible for addiction [33]. Overall, our results argue
in favor of very early relief of pain during emergency triage that avoids conventional routes.
The use of INS might become a pragmatic option in all situations where obtaining a venous
access is a challenge or delays pain management. Thus, INS could be an alternative to IV anal-
gesia in the pre-hospital setting, when IV access is not feasible or very difficult to obtain.
This randomized and double-blinded study should minimize most of the common biases.
Nevertheless, our study has a number of limitations. Despite the random assignment, there
was imbalance between the study arms in the male/female ratio and in the concomitant anal-
gesics used. Allowing co-analgesia only after 30 minutes could have avoided this bias. On the
other hand, opioid drugs are generally used as co-analgesics, in combination with acetamino-
phen in particular. From this point of view, the chosen methodology was closer to what hap-
pens in real clinical practice. As co-analgesia was more often used in the IVM group, this
imbalance might have reduced the observed efficacy of INS compared to IVM but does not
call into question the interpretation of non-inferiority. Although recruitment was lower than
expected over the planned duration of the study, the power remained above 80%, with an
effective standard deviation in reduction in pain lower than planned. The relatively low rate of
participant inclusion was due to the difficulty of implementing a randomized trial during tri-
age of patients experiencing intense pain. Finally, the study was not powered to answer the
question of safety. Although the number of severe events observed was not statistically differ-
ent between the 2 treatment groups, we observed an imbalance between the groups. The con-
firmation of safety would require a much larger trial. Future studies will also need to ensure
that the use of INS is effective and safe in other emergency settings, such as pre-hospital or in
difficult situations, such as in mountain rescue.
Table 2. Adverse events observed.
Event or symptom declared IVM (n = 69) INS (n = 67) p-Value�
Severe adverse events 2 (2.9) 6 (9.0) 0.16
Hypoxemia (SpO2 < 90%) 1 (1.5) 3 (4.5) 0.36
Hypotension (SBP < 90 mm Hg) 1 (1.5) 1 (1.5) 1.00
Bradypnea (RR < 10/minute) 0 (0) 2 (3.0) 0.24
Anaphylactic shock 0 (0) 0 (0) —
Alteration of consciousness (Ramsay > 2) 0 (0) 0 (0) —
Bradycardia (bpm < 45/minute) 0 (0) 0 (0) —
Naloxone use 0 (0) 0 (0) —
Mild adverse events 42 (60.9) 31 (46.3) 0.09
Dizziness 25 (36.2) 19 (28.4) 0.33
Hot flushes 20 (29.0) 12 (17.9) 0.13
Nausea or vomiting 13 (18.8) 8 (11.9) 0.27
Bad taste/smell 3 (4.4) 2 (3.0) 1.00
Mild allergic reaction 1 (1.5) 1 (1.5) 1.00
Epistaxis/rhinorrhea 1 (1.5) 0 (0) 1.00
Hallucinations 0 (0) 0 (0) —
Values are numbers (percentages).
�Fisher exact test or chi-squared test.
bpm, beats per minute; INS, intranasal sufentanil; IVM, intravenous morphine; RR, respiratory rate; SBP, systolic
blood pressure.
https://doi.org/10.1371/journal.pmed.1002849.t002
Intranasal sufentanil in severe trauma pain
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002849 July 16, 2019 12 / 15
In conclusion, our results suggest that IN titration of sufentanil starting at an initial dose of
0.3 μg/kg is non-inferior to IVM for trauma-related pain reduction over the first 30 minutes.
Moreover, the findings from our trial suggest that INS may be superior to IVM within this
timeframe, although our results did not show a clinically significant difference. The IN route,
with no need to obtain a venous route, may allow faster initiation of effective analgesia. Further
larger studies are needed to determine the safety profile of INS.
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